Abstract: The zebrafish is now an important model organism for cancer biology studies and provides some unique and complementary opportunities in comparison to the mammalian equivalent. The translucency of zebrafish has allowed in vivo live imaging studies of tumour initiation and progression at the cellular level thus providing novel insights into our understanding of cancer. Here we summarise and discuss available transgenic zebrafish tumour models and what we have gleaned from them with respect to cancer inflammation. In particular, we focus on the host inflammatory response toward transformed cells during the pre-neoplastic stage of tumour development. We discuss features of tumour associated macrophages and neutrophils in mammalian models and present evidence which supports the idea that these inflammatory cells promote early stage tumour development and progression. Direct live imaging of tumour initiation in zebrafish models has shown that the intrinsic inflammation induced by pre-neoplastic cells is tumour promoting. Signals mediating leukocyte recruitment to pre-neoplastic cells in zebrafish correspond to signals mediating leukocyte recruitment in mammalian tumours. The activation state of macrophages and neutrophils recruited to pre-neoplastic cells appears to be heterogenous, as seen in mammalian models, which provides an opportunity to study the plasticity of innate immune cells during tumour initiation. Although several potential mechanisms are described that might mediate the trophic function of innate immune cells during tumour initiation in zebrafish, there are several unknowns that are yet to be resolved. Rapid advancement of genetic tools and imaging technologies for zebrafish will facilitate research into the mechanisms that modulate leukocyte function during tumour initiation and identify targets for cancer prevention.

Keywords: zebrafish; inflammation; tumour initiation; macrophage; neutrophil; cancer; pre-neoplastic; live imaging; tumourigenesis; Tumour model;
1. Introduction

It has been well documented by pathologists that tumour masses are often densely packed with cells of both adaptive and innate arms of the immune system. In 1986, Dvorak first drew the comparison between tumour formation and wound healing, famously describing tumours as “wounds that do not heal” [1]. More recently, Hanahan and Weinberg have highlighted the significance of inflammation as an enabling hallmark in their updated version of “Hallmarks of Cancer” [2]. Inflammatory cells within the tumour microenvironment play a role in promoting tumour progression and metastasis and a high index of innate immune cell infiltration is often associated with poor prognosis [3,4]. Moreover, it is known that inflammation caused by pre-existing chronic inflammatory conditions conveys a predisposition to cancer development (the “extrinsic pathway”), whilst genetic events leading to neoplastic inflammation themselves promote recruitment of inflammatory cells into tumours (the “intrinsic pathway”) [5]. However, it is only in recent years that in vivo imaging studies have captured the initial inflammatory response of macrophages and neutrophils in response to oncogene expression in pre-neoplastic cells (PNCs) [6]. More importantly, these studies show that intrinsic (i.e. PNC-induced) inflammation begins to exert a trophic influence on PNC growth even at this nascent stage of cancer development [6,7]. These findings demonstrate the advantages of using zebrafish to model cancer and live imaging approaches to uncover novel aspects of cancer biology. In particular, zebrafish facilitate the study of cellular dynamics during the initial phase of tumour development, a stage previously thought intractable to study.

The zebrafish has been a major vertebrate model for developmental biology since the 1960’s. Several forward genetic screens lead to the identification of mutants affecting almost every organ and cell type, and most of the causative genes identified were found to be conserved in the human [8]. The complete zebrafish reference genome shows that 70% of the human genome has at least one conserved orthologue in zebrafish [9]. Naturally occurring neoplastic lesions were observed in wild type zebrafish reared under laboratory conditions [10], and major cancer-related genes that affect humans are conserved in zebrafish, allowing for their direct comparison e.g. the master tumour suppressor, p53 [11], and components of the MAPK pathways [12]. Due to the ease of genetic manipulation, high fecundity and translucency at the larval stage, the zebrafish is now an important player in cancer research.

In this review we discuss the benefits of zebrafish transgenic models that facilitate in vivo live imaging studies of tumour initiation. We describe the studies conducted in zebrafish that have allowed the field to establish the significance of early host inflammatory responses in promoting cancer develop at the pre-neoplastic stage. Furthermore, we summarise evidence from the literature suggesting that these inflammatory components are conserved in mammalian tumourigenesis by drawing upon the limited studies of early inflammation within mouse and human neoplastic legions. We highlight the signals required for the recruitment of macrophages and neutrophils to PNCs and the heterogeneous nature of their responses. Finally, we discuss recent technical advances within the zebrafish field that will facilitate further research of the pro-tumour inflammatory response and the potential discovery of cancer prevention strategies.

2. Zebrafish transgenic models of cancer for in vivo live imaging studies of tumour initiation

Zebrafish larvae develop most major organs, vasculature and a fully functional innate immune system within the first 5 days post fertilization. Most significantly, they are naturally transparent. This transparency, combined with fluorescent labels, allows real-time observation of single cells in a live in vivo model. Furthermore, by deleting genes required for pigmentation, the Casper strain has been created, which remains translucent throughout adulthood [13]. The most evident benefit of using zebrafish as a cancer model is the capacity for in vivo live imaging. For example, the first transgenic zebrafish model for cancer was a T cell leukaemia model, which was established by expression of the mouse homologue of oncogene c-myc, tagged with fluorescent GFP, under the
control of the T-cell specific promoter, Rag2 [14]. This model allowed direct monitoring of the initiation and expansion of leukaemic cells from the thymus by fluorescence microscopy [15].

Since establishment of the Tol2 transposase transgenesis protocol for zebrafish, generation of transgenic strains has become a routine procedure [16,17]. This has accelerated the development of zebrafish cancer models, many of which mirror human disease in terms of both histopathological features and molecular signatures. For example, zebrafish melanoma models expressing the common melanoma oncogenes BRAFV600E, NRASQ61K and HRASG12V under the melanocyte-specific mitfa promoter, or HRASG12V under the kita promoter, are all sufficient to drive melanoma tumour formation, either alone or in combination with p53−/− mutation [18–21]. These models all recapitulate human melanoma with respect to their hyperpigmentation, histology and, where tested, their transcriptomic gene expression profiles [20,21]. The expression of human oncogenes under the control of tissue specific promoters has also been employed to create representative cancer models for various organs, including the pancreas [22], liver [23], colon [24] and brain [25] (See Table 1).

Zebrafish models of cancer commonly feature fluorescently tagged oncogenes which label cancer cells and allow real time monitoring of tumour promotion and progression. Furthermore, the creation of “transgenic reporters” also allows the visualisation of gene expression by expression of fluorescent proteins under the control of the promoter region of a gene of interest. As such, zebrafish models offer a unique contribution to the field of cancer biology, by capturing events which cannot be directly observed in mammalian in vivo models, such as tumour initiation and metastasis. This review focuses upon the use of zebrafish for the study of tumour initiation, while the application of zebrafish for the study of metastasis has been reviewed by Osmani & Goetz, 2019 [26].

Tumour initiation is the first stage of cancer development, during which normal cells undergo changes that enable them to form tumours. The combination of live imaging with genetic and chemical manipulations in zebrafish has allowed the dissection of novel mechanisms involved in tumour initiation. For example, transgenic reporters have been utilised to study genetic mutations and key signaling pathways that contribute to tumour initiation [27,28]. A central question in our understanding of tumour initiation is why only a small proportion of mutant pre-neoplastic clones go on to form tumours. Multiple zebrafish models have been used to explore the fate of pre-neoplastic cells, uncovering a mechanism by which de-differentiation conveys a tumour initiating fate. By combining live imaging with a transgenic reporter for the developmental gene, crestin, the de-differentiation of single clones within pre-neoplastic legions was observed, followed by an acceleration of tumorigenic activity [29]. A related phenomenon was also observed in a zebrafish model of pancreatic tumour initiation, in which labelling tumour initiating cells with a marker of differentiation revealed that expression of KRASG12D blocked differentiation, leading to tumourigenesis [22]. Interestingly, live imaging has also led to the observation that cells expressing oncogenic Ras or v-Src can be extruded from the epidermis by healthy neighboring cells, indicative of a potential tumour-suppressive defense mechanism [30–32].

The main limitation in the use of transgenic models to study tumour initiation is that oncogene expression is dependent upon tissue specific promoters, for which timing of activation can vary. This also restricts the study of early events to larval zebrafish. However, inducible systems for transgene expression have been appropriated from the Drosophila and mouse fields, including the Tet/On system [33], the Lex/PR system [34], Tamoxifen-inducible GAL4/UAS [35] and heat-shock inducible Cre/Lox [36]. These systems have recently been used to develop inducible cancer models, which now enable temporal precision for the study of tumour initiation in both larval and adult fish [37–41].

In addition to the use of zebrafish for the study of cancer biology, the zebrafish has also been widely used for the study of innate immune responses with respect to host-pathogen interactions [42] and wound healing [43,44]. Considering the importance of inflammation in the development and progression of cancer, zebrafish researchers have turned their attention to the study of macrophages and neutrophils in relation to cancer. Fluorescent transgenic reporter lines for both macrophages and neutrophils have been developed using the macrophage specific promoters,
mpeg [45] or mfp4 [46], and neutrophils specific promoters, mpo [47] or lyz [48], (see Table 2). In this way, the dynamics of the immune response can be directly imaged, allowing live in vivo visualisation of the interactions between leukocytes and cancer. Studies combining zebrafish cancer models with leukocyte markers have demonstrated that zebrafish macrophages and neutrophils have tumour-promoting roles comparable to their mammalian counterparts (see section 3). Furthermore, modelling tumour initiation in zebrafish has elucidated mechanisms of tumour promoting inflammation which had never before been captured at this early stage (see section 5).

Table 1. Established Transgenic Zebrafish Cancer Models

| Zebrafish lines with transgenic oncogenes | Oncogene | Promoter | Marker | Tumour type | References |
|------------------------------------------|----------|----------|--------|-------------|------------|
| Tg(4.9k-krt5:Gal4VP16-UAS-mCherry-KRASG12V) | KrasG12V  | Keratin 5 | mCherry | Brain cancer | [49]       |
| Tg(gfp:Gal4VP16-UASmCherry-KRASG12V) | KrasG12V  | glial fibrillar acidic protein | mCherry | Brain cancer (glial cells) | [49]       |
| Tg(gfp:GFP-KrasG12V) | KrasG12V  | glial fibrillar acidic protein | eGFP | Brain tumour (glial cells) | [50]       |
| Tg(fabp10:p53-β-catenin; fabp10:rasGFP) | Constitutively active β-catenin | fatty acid binding protein 10 | eGFP | Hepatocellular carcinoma | [51]       |
| Tg(fabp10:TAa2-m2; TRE2:EGFP-krasG12V) | KrasG12V  | fabp10; Tet-On system inducible by doxycycline | eGFP | Liver cancer (hepatocytes) | [52-54]  |
| Tg(Xef1a:EGFP-TEL-AML) | Human ETV6 and RUNX1 fusion | Xenopus laevis elongation factor 1a | eGFP | Lymphoblastic leukemia | [55]       |
| Tg(actb2:EGFP-TEL-AML) | Human ETV6 and RUNX1 fusion | Zebrafish beta actin | eGFP | Lymphoblastic leukemia | [55]       |
| Tg(mitfa:HRASG12V; mitfa:GFP/mCherry) | HRASG12V  | melanocyte inducing transcription factor a | eGFP/ mCherry | Melanoma | [20]       |
| Tg(kita:Gal4TA-UAS:GFP-HRASG12V) | HRASG12V  | KIT proto-oncogene, receptor tyrosine kinase a | eGFP | Melanoma | [6,7,21]  |
| mitfa:BRAFV600E/P533− | BRAFV600E/P533− | melanocyte inducing transcription factor a | N/A | Melanoma | [18]       |
| Tg(mita:LexPR-Cereulan;LexOP:mCherry-NRasG12K) | NRasG12K  | melanocyte inducing transcription factor a; mifepristone-inducible LexPR system | mCherry | Melanoma | [56]       |
| Tg(kita:LexPR-Cereulan;LexO PmCherry-NRasG12K) | NRasG12K  | KIT proto-oncogene, receptor tyrosine kinase a; mifepristone-inducible LexPR system | mCherry | Melanoma | [56]       |
| Tg(dp1he:EGFP-MYCNI) | MYCN | dopamine-β-hydroxylase | eGFP | Neuroblastoma | [28]       |
| Tg(dp1he:EGFPdp1he:ALK127V) | ALK127V  | dopamine-β-hydroxylase | eGFP | Neuroblastoma | [28]       |
| Tg(ptt1ae:GFP-KRASG12V) | KRASG12V  | pancreas Associated Transcription Factor 1a | eGFP | Pancreatic cancer | [22]       |
| Tg(Pomc:Pttg; Ppmce:GFP) | PTTG | Pituitary proopiomelanocortin | eGFP | Pituitary adenoma | [57]       |
| Tg(nag2:KRASG12V; nag2:εGFP) | KRASG12V  | recombination activating gene 2 | eGFP | Rhabdomyosarcoma | [58,59]  |
| Tg(cdh15:KRASG12V;myl5:εGF P or myl22:εmCherry) | KRASG12V  | cadherin 15 | eGFP/ mCherry | Rhabdomyosarcoma | [60]       |
| Tg(myl22:KRASG12V; myl22:εmCherry) | KRASG12V  | myosin light chain, phosphorylatable, fast skeletal | mCherry | Rhabdomyosarcoma | [60]       |
muscle a

Kras, Kirsten rat sarcoma viral oncogene homolog; ETV6, ETS Variant Transcription Factor 6; RUNX1, runt-related transcription factor 1; Hras, Harvey rat sarcoma viral oncogene homolog; Braf, B-Raf proto-oncogene, serine/threonine kinase; Nras, neuroblastoma RAS viral oncogene homolog; Mycn, MYCN proto-oncogene bHLH transcription factor; Alk, anaplastic lymphoma kinase; Pttg, pituitary tumour transforming gene; C-myc, C-Master Regulator of Cell Cycle Entry and Proliferative Metabolism.

Table 2. Zebrafish Transgenic Reporter Lines for Innate Immune Cells

| Transgenic line name                                                                 | Promoter          | Marker                  | References |
|---------------------------------------------------------------------------------------|-------------------|-------------------------|------------|
| Tg(mpx:mCherry)                                                                      | myeloperoxidase   | mCherry                 | [50]       |
| Tg(mpx;GFP), Tg(BACmpo:eGFP), zMPO                                                   | myeloperoxidase   | GFP                     | [6, 61, 62]|
| Tg(mpx:EGFP-L10a)                                                                    | myeloperoxidase   | eGFP-L10a targeted to ribosomes and polysomes | [62]       |
| TgBAC(mpx:BirA-Citrine)ox121; Tg(bactin:Avi-Cerulean-RanGap)x700a                    | myeloperoxidase   | Citrine; conditional system for biotin-tagging nuclei of neutrophils | [56]       |
| Tg(LysC:DsRed)                                                                       | Lysozyme C        | dsRed                   | [6, 7, 52–54, 63] |
| Tg(mpeg1:Dendra)                                                                      | macrophage expressed 1 | Dendra                 | [62]       |
| Tg(mpeg1:eGFP)                                                                       | macrophage expressed 1 | eGFP                   | [40, 53, 54, 63] |
| Tg(mpeg1:FRET)                                                                       | macrophage expressed 1 | FRET                   | [63]       |
| TgBAC(mpeg1:BirA-Citrine)ox122; Tg(bactin:Avi-Cerulean-RanGap)x700a                   | macrophage expressed 1 | Citrine; conditional system for biotin-tagging macrophage nuclei | [56]       |
| Tg(fli1a:eGFP)                                                                        | Fli-1 proto-oncogene, ETS transcription factor; expressed in endothelium and myeloid lineages in early larva | eGFP       | [6]       |

Table 2. presents transgenic lines used within the studies referenced within this review and is my no means an exhaustive list of available lines.

3. Macrophages and neutrophils are co-opted by cancer to perform tumour-supporting activities

High levels of macrophages and neutrophils in cancerous lesions correlate with poor prognosis in humans. The pro-tumour activities of these leukocytes are evident in both mammalian and zebrafish models.

a. Tumour Associated Macrophages

Tumour associated macrophages (TAMs) are the most abundant leukocyte found within tumours, comprising up to 50% of the tumour mass in epithelial tumours [64, 65]. The degree of macrophage infiltration correlates with poor clinical prognosis across a broad range of tissue types [3]. Both tissue resident macrophages and blood monocyte-derived macrophages infiltrate tumours, where they are influenced by signals derived from cancer cells and the local tumour microenvironment to perform tumour promoting activities [66]. The activation state of TAMs more
closely resembles that of “alternative” or “anti-inflammatory” M2 polarization, as opposed to “classical” or “pro-inflammatory” M1 polarization, e.g. genes commonly expressed by TAMs include scavenger receptors, arginase-I, matrix metalloproteinases, TGF-β and IL-10, accompanied by downregulation of pro-inflammatory cytokines and MHC Class II [67,68]. Although, it is of note that the concept of M1/M2 polarisation is an oversimplification and TAMs are a highly heterogenous population [3,69–71]. The tumour supporting roles of TAMs have been studied extensively in the past two decades, revealing mechanisms by which TAMs promote proliferation, angiogenesis, invasion and metastasis [72–75]. In zebrafish cancer xenograft models, zebrafish macrophages have also been shown to promote angiogenesis, invasion and metastasis [76,77].

3.2 Tumour Associated Neutrophils

Neutrophils are frequently found within tumours and, following the convention of TAMs, the term “Tumour Associated Neutrophil” (TAN) has now been adopted. However, TANs are less well characterised in comparison to their TAM counterparts and have been shown to have both pro- and anti-tumour effects [78]. Nonetheless, in numerous studies a high intra-tumour neutrophil density has been associated with poor patient prognosis [79,80]. Multiple tumour promoting functions of TANs have been described, including the encouragement of proliferation, angiogenesis, metastasis and immunosuppression [78,81,82]. In addition, through secretion of genotoxic nitric oxide and reactive oxygen species (ROS) neutrophils exert a mutagenic effect and provide a further driver for cancer development. However, higher levels of nitric oxide release from neutrophils can be cytotoxic for cancer cells, contributing to tumour suppression [83,84]. Further anti-tumour roles of neutrophils may include triggering apoptosis via activation of TRAIL [85] and promoting the activity of anti-tumour cytotoxic T lymphocytes [86]. In zebrafish, tumours also exhibit high levels of infiltrating neutrophils, which promote metastasis and express genes involved in angiogenesis and immunosuppression [62,87–89]. Anti-tumour neutrophil responses have yet to be described within zebrafish cancer models.

In addition to mature neutrophils, under pathogenic conditions such as chronic inflammatory disease and cancer, immature myeloid cells, known as myeloid-derived suppressor cells (MDSCs), are recruited from the bone marrow prior to terminal differentiation [68,90]. Granulocytic MDSCs (G-MDSCs) are thought to be immature neutrophils since they morphologically and phenotypically resemble neutrophils. G-MDSCs promote tumour cell survival, angiogenesis, invasion, metastasis, and immunosuppression; functions similar to those of mature pro-tumour TANs [91]. In contrast, existing studies have not described anti-tumour functions for G-MDSCs [92]. It is of note that not all cancer studies make a clear distinction between mature TANs and immature G-MDSCs, and there is a lack of clarity as to whether they are independent cell types or whether they originate from the same progenitors [92–94]. The existence of MDSCs has not been explored in zebrafish and it is uncertain whether neutrophils in zebrafish cancer studies are recruited in a mature or immature state.

4. Evidence of tumour-promoting inflammation in early tumourigenesis of mouse and man

Whilst there is abundant evidence that TAMs and TANs have tumour promoting roles within established tumours, relatively little is known about the role of macrophages and neutrophils at the earliest stage of tumour initiation. This is largely because the early stages of tumourigenesis are difficult to detect in humans and mammalian models. The exception to this is colorectal cancer. At the early neoplastic stage, distinctive structures known as “adenomatous polyps” are formed [95]. These polyps are easy to detect and their removal is a routine procedure. Furthermore, the common initiating mutation, APC, was discovered over 30 years ago by studying families with Familial Adenomatous Polyposis (FAP). FAP is caused by an inherited mutation in the APC gene, leading to abundant polyp formation and, without intervention, malignant disease [96,97]. This discovery was swiftly followed by the creation of APC mutant mouse models which represent not only FAP but also spontaneous colorectal cancers, 80% of which feature mutations in APC [98,99]. The ability to
detect and model early neoplastic legions in this way enabled the discovery of factors which promote early tumourigenesis, such as Prostaglandin E2 (PGE2).

PGE2 is a potent inflammatory mediator, synthesised by the COX-2 enzyme. Both PGE2 and COX-2 are present at high levels in colorectal cancer, adenomatous polyps and even pre-neoplastic microadenoma [100,101]. Chemical inhibition of COX-2, as well as the deletion of the COX-2 gene or various PGE2 receptors, was found to dramatically decrease intestinal polyp formation in numerous mouse models of colorectal cancer, including APC mutant mice and mice exposed to carcinogens [102–106]. Non-sterile anti-inflammatory drugs (NSAIDs) such as sulindac and COX-2 inhibitor celecoxib, have been tested for the prevention of both FAP and spontaneous colorectal cancers and have proven to effectively reduce polyp formation and prevent cancer [107–109]. Epidemiological studies have also shown that use of COX-2 inhibitor, aspirin, is associated with decreased incidence of colorectal cancer [110]. Unfortunately, the use of COX-2 inhibitors to prevent cancer is limited due to dangerous cardiovascular side effects associated with long term use [111].

PGE2 is also implicated in the promotion of many other types of cancer, including cancer of the breast [112], liver [113], lung [114], brain [115], and pancreas [116,117]. This suggests that the phenomenon by which inflammation fuels early tumour promotion may be a common feature of cancer development. Therefore, the discovery of alternative methods to target this early inflammatory response is imperative for cancer prevention. Inhibiting the recruitment of either macrophages or neutrophils also dramatically reduced polyp formation and prevented carcinoma in mouse colon cancer models [118–121]. This demonstrates the importance of inflammatory leukocytes in promoting early tumourigenesis. As such, both macrophages and neutrophils are promising targets for cancer prevention, but further research is required to understand precisely when and how along the pathway of oncogenesis leukocytes are recruited and co-opted by the cancer cell.

Research in this field has been impeded by a lack of suitable in vivo models. Most mouse models for the study of tumourigenesis rely on read-outs such as tumour size and occurrence, whilst measurements of the early pre-neoplastic stage are largely missing. These models also lack temporal resolution and the means to dissect complex mechanisms involving interactions between multiple cell types. For these reasons, the zebrafish is a uniquely advantageous model for the study of inflammation during early tumourigenesis.

5. Zebrafish studies reveal leukocyte recruitment and trophic function at the pre-neoplastic stage

Studies utilising transparent zebrafish larvae to model tumour initiation were the first to report a trophic inflammatory response at the pre-neoplastic stage. Feng et al. 2010 first showed that leukocytes are rapidly recruited following the expression of a single oncogene [6]. Subsequent zebrafish studies have shown a similarly rapid recruitment of neutrophils and/or macrophages to the skin, liver and brain in response to transgenic expression of numerous oncogenes e.g. HrasG12V, KrasG12V, NRasQ61K, Src, Xmrk, Myc and Akt [6,7,37,38,40,50,53,56,62,122,123]. Live imaging has provided insight into the dynamics of the intrinsic inflammatory response following tumour initiation within these models. Furthermore, the depletion of leukocytes revealed that both macrophages and neutrophils have a potent tumour-promoting effect as early as the pre-neoplastic stage. Here we highlight the details of these findings within each tissue type:

5.1 Skin

In vivo live imaging with fluorescent leukocyte markers in the Tg(kita:Gal4TA,UAS:eGFP-HRASG12V) melanoma model showed that leukocytes are recruited to PNCs at the earliest stage of tumour initiation, even prior to the expansion of single clones [6]. Retention of leukocytes in the PNC microenvironment was sustained over time, indicative of chronic non-resolving inflammation. The up-regulation of pro-inflammatory cytokines in PNC-bearing larvae further confirmed an early onset inflammation in response to tumour initiation. Hydrogen peroxide (H2O2), a potent chemoattract at wounds, was identified as the local chemoattractant
guiding neutrophils towards PNCs. This discovery was facilitated by the use of live imaging which allowed a direct comparison of neutrophil dynamics between tumour initiation and wounding, and the use of a fluorescent H₂O₂ probe to visualise secretion from PNCs. Although both neutrophils and macrophages were observed to engulf material from PNCs, pan-leukocyte depletion (by Gcsfr + PU.1 morpholino) lead to a greatly decreased number of PNCs demonstrating their pro-tumour function [6,7]. Neutrophil depletion alone (using Gcsfr morpholino) lead to greater reduction of PNCs than macrophage depletion alone (using Irf8 morpholino), suggesting that neutrophils have a greater contribution to trophic inflammation in this model. Furthermore, PGE₂ was found to be one of the trophic factors released by leukocytes, to directly promote PNC proliferation through the EP1 receptor [7]. It is of note however, that exogenous PGE₂ only partially rescued PNC number in pan-leukocyte depleted larvae which suggests that leukocytes produce additional, non-redundant trophic signals.

A more precise temporal resolution of the inflammatory response to tumour initiation was observed by tamoxifen-inducible transformation of keratinocytes with GFP-tagged HRAS<sup>G12V</sup>. Here, neutrophils were recruited within 8 hours post induction (hpi) and leukocyte depletion resulted in a 50% reduction of PNC number at 48hpi [124]. By using correlative light and electron microscopy (CLEM) to study leukocyte recruitment in this model, it was observed that the dominant route by which immune cells gain access to PNCs is through proteolysis-independent breach of weak spots on basement membrane. However, proteolysis-dependent damage to the basement membrane was seen underneath areas of PNC clonal expansion, which suggests that PNCs can have invasive properties. Indeed, HRAS<sup>G12V</sup> transformed keratinocytes expressed the invasion-related genes Mmp9 and Slug [62]. PNCs also expressed the chemokine, IL-8, which was shown to attract neutrophils via CxcR2. Interestingly, reduced neutrophil recruitment also partially attenuated the expression of mmp9 and slug in PNCs, suggesting that neutrophils encourage the invasive behavior of PNCs. Transcriptomic analysis of PNC-associated neutrophils in an NRAS<sup>Q61K</sup> melanoma model, showed upregulation of genes that correspond with growth- and invasion-promoting properties, e.g. FGF-1 and -6, cathepsin-H and galectin 1 and -3 [56].

5.2 Liver

Using the Tet-On system to induce KRAS<sup>G12V</sup> expression in the hepatocytes of zebrafish larvae triggered a trophic inflammatory response in the liver [40]. As seen in response to tumour initiation in the skin, neutrophils are recruited at approximately 8hpi. Upon entering the liver, neutrophil motility was decreased, indicative of a chronic inflammatory response. Such retention behavior has also been observed for TANs, in mouse tumour models [125]. Following induction of KRAS<sup>G12V</sup>, both PNCs and neutrophils expressed high levels of IL-1β and TGF-β. Targeting TGF-β signaling, by neutralising antibody or TGFBR1 inhibition, reduced both liver size and the number of infiltrating neutrophils, as well as triggering upregulation of pro-inflammatory genes (IL-1β, TNFα, IL-6, IL-8, IL-12) indicating TGF-β is a key modulator of neutrophil function in the pre-neoplastic microenvironment of the liver.

The Tet-On inducible system also allowed Yan et al. (2017) to explore the role of both neutrophils and macrophages upon induction of KRAS<sup>G12V</sup> in the adult fish liver [54]. PNCs expressed both the neutrophil chemoattractant IL-8 and macrophage chemoattractant CSF-1 at 7dpi, and an array of pro-inflammatory genes were upregulated in both macrophages and neutrophils (IL1-b, Cxc11b, Nfkb2, CSF-1, IL-6 and IL-8). Leukocyte depletion completely attenuated the increased in PNC proliferation and survival observed in leukocyte-bearing larvae, returning the size of the liver to that of wild-type. Depletion of macrophages had a comparable effect compared to the depletion of neutrophils; both resulted in a partial attenuation of liver enlargement and equivalent reduction in PNC proliferation, suggesting that both cell types provide important trophic signals. A cortisol-dependent sex bias in disease severity was observed in male fish consistent with that observed in human Hepatocellular Carcinoma (HCC). TGF-β expression and the levels of both macrophages and neutrophils in the liver were strongly correlated with this bias, further implicating TGF-β as a mediator of pro-tumour inflammation.
Transformation with other common HCC oncogenes, Xmrk and Myc, also elevated the expression of TGF-β in PNCs and triggered neutrophil and macrophage recruitment to the liver [53]. This demonstrates that oncogene-dependent inflammation is not specific to KRASG12V. β-catenin overexpression also caused oncogenic transformation in hepatocytes, with associated recruitment of macrophages and neutrophils [126]. Whilst the independent influence of oncogene-dependent inflammation has yet to be determined in this model, a combination of β-catenin expression and high fat diet induced a strong tumour promoting inflammatory response, which was associated with TNFα positive macrophages. Finally, modelling a rare type of liver cancer (Fibromellar Carcinoma), by transgenic expression of a Dnja1-PKAc fusion protein, resulted in leukocyte recruitment to the liver [127]. Here too, an increase of TNFα positive macrophages was observed, alongside a liver-wide activation of caspase-1 indicating inflammasome activation and IL-1β release. Chemical inhibition of either TNFα or caspase-1 reduced neutrophil and macrophage numbers to wild-type levels, demonstrating the potency of these cytokines as recruitment factors.

5.3 Brain

Glioblastoma can be modelled in the zebrafish by transgenic overexpression of Akt in neural cells, a gene commonly upregulated in human glioblastoma [128]. Oncogenic Akt transformation lead to an overabundance of microglia in the brain, which exhibited reduced mobility, sustained contact with PNCs, and a distinctive amoeboid morphology indicative of activation. Live imaging combining both macrophage- and microglia-specific reporters showed that the increase in microglia numbers was due to a recruitment of peripheral macrophages, which subsequently differentiated into microglia upon entry into the brain parenchyma. Treatment with anti-inflammatory drug dexamethasone or partial inhibition of macrophage recruitment by inhibition of CSF-1R reduced PNC proliferation. Complete abrogation of macrophage recruitment by Irf8−/− or Cxcr4−/− resulted in even greater suppression of PNC proliferation, showing a potent trophic role of macrophages / microglia during glioblastoma initiation and a requirement for Cxcr4.

Interestingly, microglia mediated trophic support to PNCs in the brain might be cell contact dependent. By live imaging, using the GCamP6f transgenic Ca2+ reporter, Chia et al. (2019) discovered that PNC-microglia interactions are governed by Ca2+-dependent ATP release and detection of extracellular ATP by the P2y12 receptor [123]. This mechanism is normally employed under physiological conditions which govern recruitment of microglia to highly active neurons [123,129–132]. Reduction of Ca2+ levels, inhibition of ATP release, or inhibition of the P2y12 receptor all significantly abrogated PNC-microglia interactions and greatly reduced the rate of PNC proliferation, equivalent to that of macrophage/microglia depletion described above [123,128]. Therefore, ATP-P2y12 signaling, and possibly direct PNC-microglia contact, were required for the tumour promoting effect of Akt-dependent inflammation in the brain.

Whilst Chia et al. (2018) reported an absence of neutrophils in the brain during Akt-dependent tumour initiation, in contrast, neutrophil recruitment into the brain was observed by Powell et al. following KRASG12V transformation of astrocytes [50,122]. Although there is a discrepancy between these studies, both peripheral macrophage and neutrophils are found within human brain tumours [133]. In this case, KRASG12V-expressing astrocytes also expressed high levels of IL-8 and blocking neutrophil recruitment by abrogation of Rac2 or Cxcr1 significantly reduced the proliferation of pre-neoplastic astrocytes [50]. This suggests a trophic role of neutrophils in during tumour initiation in the brain, and demonstrated the requirement of IL-8-Cxcr1 signaling for neutrophil recruitment.

6. Mechanisms governing intrinsic pro-tumour inflammation: Parallels between zebrafish, mouse and man

Overall, the above zebrafish studies have identified numerous signals involved in the activation and recruitment of inflammatory leukocytes in response to tumour initiation and trophic signals that feedback on PNC proliferation. Although equivalent studies of the pre-neoplastic stage do not exist in mammalian models, there is evidence that these signals exist at early stages of mammalian
tumourigenesis. Mammalian studies also provide mechanistic clues as to how these signals govern tumour-promoting inflammatory responses.

6.1 Pro-inflammatory cytokines are expressed in response to tumour initiation

Zebrafish skin and liver cancer models showed an upregulation of the pro-inflammatory cytokines IL-1β and TNFα in response to tumour initiation [6,50,54,126,127,134]. Both of these inflammatory cytokines were important for the recruitment of leukocytes to the liver [127].

In mouse models of skin and colon cancer, knock-out of IL-1β/IL-1R or downstream signal transducer, MyD88, lead to a dramatic and sustained abrogation of leukocyte recruitment in addition to a reduced occurrence of colon polyps and skin papillomas [135–137]. This demonstrates that IL-1β is required for instigating tumour-promoting inflammation during early tumourigenesis in mice. IL-1β activates and amplifies host inflammatory responses by activation and recruitment of innate immune cells via expression of pro-inflammatory cytokines and chemokines [138,139]. In support of this mechanism in response to tumour initiation, in vitro studies have shown that IL-1β, TNFα and IL-6 expression are induced by transformation with oncogenic Ras in various human and mouse cell types [137,140–144].

Knock-out of TNFα or TNFR1 also reduced leukocyte infiltration and increased resistance to tumour development in mouse models of skin and liver cancer [145–147]. TNFα signaling is well-established to upregulate pro-inflammatory cytokines and chemokines, and can itself act as a chemotactact signal, which may explain the requirement of TNFα for leukocyte recruitment in both zebrafish and mouse studies [148]. Dichotomously, TNFα signaling can also directly induce apoptosis of cancer cells, or promote cell survival through activation of NF-κB signaling [148]. Although the direct effect of TNFα upon PNCs has not been explored in zebrafish models of tumour initiation, the latter mechanism is more likely since no signs of leukocyte-mediated cell death have been recorded and TNFα positive macrophages promote tumourigenesis in zebrafish liver cancer models [54,127].

6.2 Chemokines recruit leukocytes to PNCs

Zebrafish models of both brain and liver cancer have indicated that CSF-1 contributes to the recruitment of macrophages in response to tumour initiation [54,128]. Likewise, CSF-1 signaling is a well-established macrophage recruitment signal in mammalian cancers [149–153]. With respect to early tumourigenesis in mice, abrogation of CSF-1 reduced tumour formation in thyroid and pancreatic neuroendocrine cancer models [154,155]. However, blocking CSF-1 in breast cancer models only affected progression to invasive metastatic carcinoma [156]. Similarly, in the development of mouse colon cancer, lack of CSF-1 lead to a modest reduction in the number of small polyps but a dramatic reduction in the number of large polyps, again suggesting a role in promoting progression [157]. Therefore, CSF-1 involvement during tumour initiation might be tissue-specific. In addition to its role in macrophage recruitment, CSF-1 contributes to control of the M2 phenotype of mammalian TAMs; both pre-clinical and clinical studies have shown that inhibition of CSF-1 does not always deplete TAMs from established tumours, but rather impairs their tumour-promoting functions [153,158]. This suggests that other factors also drive the recruitment and retention of macrophages in cancer.

Chia et al. (2018) showed that, whilst CSF-1 played a role in macrophage recruitment, signaling to Cxcr4 was absolutely required for the recruitment of macrophages to the Akt-transformed brain in zebrafish tumour initiation, and that PNC-derived Cxcl12 was the major ligand for this interaction [122]. Cxcr4 signaling has been shown to promote progression of many cancers in mammals including glioblastoma, through both cancer cell autonomous signaling and leukocyte interactions [88,159–164]. However, the pro-tumour effect of Cxcr4 signaling at the preneoplastic stage was macrophage specific [122]. In the mouse APCmin model of colorectal cancer, Cxcr4-/- mice exhibited reduced macrophage infiltration and polyp formation [165]. Furthermore, in the mouse Lewis lung carcinoma model, inhibition of Cxcr4 greatly reduced tumour associated inflammation and tumour growth [166]. Thus, there is some evidence that Cxcr4 signaling recruits macrophages and has a
pro-tumour effect during early stage tumourigenesis in mammalian models. Cxcr4 has also been implicated in the recruitment of neutrophils and G-MDSCs to cancer cells in mouse xenograft models, resulting in tumour promoting effects [165,167–169].

IL-8 was expressed in zebrafish PNCs in response to oncogenic Ras expression [54,170] and IL-8 signaling through Cxcr1/2 chemokine receptors was shown to drive pro-tumour neutrophil recruitment at the pre-neoplastic stage in zebrafish models of skin and liver cancer, contributing to PNC proliferation and sustained tumour-promoting inflammation [50,62]. Likewise, Ras-induced expression of IL-8 promotes neutrophil recruitment and tumourigenesis in mouse xenograft models [142,171,172]. IL-8 also has been found to provoke a neutrophil-dependent anti-tumour effect, consistent with the ability of TANs to perform both pro- and anti-tumour functions [173]. More broadly, Cxcr1/2 signaling has been shown to recruit pro-tumour TANs and/or G-MDSCs in a variety of mammalian cancers [174–178]. With respect to early tumourigenesis, Cxcl1 and Cxcl2 have been shown to drive neutrophil and G-MDSC infiltration in mouse models of colorectal cancer, promoting polyp and tumour formation [119,179,180]. These findings suggest that signaling via the IL-8 - Cxcr1/2 chemokine axis promotes tumour initiation.

![Image](image-url)

**Figure 1.** Signals governing the recruitment of innate immune cells in response to tumour initiation. IL-1β is secreted by PNCs in response to oncogenic transformation, activating local immune cells, which in turn express inflammatory cytokines such as IL-1β and TNFα. H2O2 released from PNCs acts as a local chemoattractant for the recruitment of inflammatory leukocytes. CSF-1 and Cxcl12 contribute to the recruitment of macrophages through interaction with CSF-1R and Cxcr4 respectively, these signals are both PNC and macrophage derived. IL-8, expressed by both PNCs and neutrophils in response to tumour initiation, is responsible for neutrophil recruitment via Cxcr1/2.

6.3 Plasticity and heterogeneity of leukocytes

The expression of pro-inflammatory cytokines by macrophages and neutrophils in response to tumour initiation in zebrafish studies corresponds with the hypothesis that tumour associated inflammation begins with a pro-inflammatory response, which becomes progressively more anti-inflammatory throughout the course of tumourigenesis [68,69,181–184]. This phenomenon mimics the wound response which, in both zebrafish and mammals, is characterised by early M1/N1 activation followed by a switch to M2/N2 activation states that promote tissue repair and resolution [43,185–187], with the exception that tumours provoke a sustained response, thus creating a positive-feedback cycle of non-resolving inflammation and tissue repair [181]. Interestingly, macrophages and neutrophils within zebrafish studies had trophic effects at the pre-neoplastic stage.
(as early as 24 hours following oncogenic transformation), and in the presence of pro-inflammatory signals [6,7]. This suggests that, in the case of intrinsic inflammation, the M2/N2 switch occurs at the pre-neoplastic stage. The simultaneity of pro-inflammatory and trophic signals may be achieved by an intermediate phenotype between M1/N1 and M2/N2, and/or heterogeneity of leukocyte responses. In support of the latter, leukocyte heterogeneity was observed in zebrafish studies of tumour initiation; only 20% of leukocytes recruited to PNCs in the skin expressed PGE synthase, whilst minor populations of macrophages stained positive for either M1 (TNFα) or M2 (arginase-1) markers [6,134]. Furthermore, in response to oncogenic transformation in the liver, only 35% of macrophages were TNFα positive [127].

6.4 PGE₂ as trophic factor and immunomodulator

As previously discussed, PGE₂ is a central component of pro-tumour inflammation in humans and mice, and has been identified as a potent leukocyte-derived trophic signal at the pre-neoplastic stage in zebrafish [134]. In support of this finding, PGE₂ is also secreted by macrophages within neoplastic polyps in humans and mice [188–190]. PGE₂ signaling has a direct trophic function in mouse models of colon cancer, for example, through activation of β-catenin [110]. Macrophage-derived PGE₂ also increases COX-2 expression in neoplastic cells, creating a positive feedback cycle which greatly increases the local level of PGE₂ in the colon, driving tumourigenesis [191].

Within mammalian immune responses and cancer, COX-2 expression is upregulated by both pro-inflammatory cytokines, such as IL-1β, and tumour promoters, such as Ras [192–195]. PGE₂ itself is a central inflammatory mediator governing both positive and negative regulation of inflammation through alternative receptors [196,197]. Whilst PGE₂ enhances early inflammation, it later exerts an immnosuppressive effect on both macrophages and neutrophils [198–202]. Thus, PGE₂ may also contribute to shaping the inflammatory response at the pre-neoplastic stage. For example, the immnosuppressive effect of PGE₂ could prevent neutrophils from performing anti-tumour activities and may contribute to the M2/N2 phenotype of pro-tumour leukocytes. Indeed, COX-2 inhibitors have been shown to repolarize M2 TAMs [203–205], and PGE₂ has been implicated in the induction of MDSCs in tumour-bearing mice [206–208].

6.5 TGF-β governs pro-tumour neutrophils

In zebrafish models of liver tumour initiation, high levels of TGF-β expression by PNCs are associated with both disease severity and the expression of anti-inflammatory genes in pro-tumour neutrophils [52,53]. The first indication of this mechanism in mammals was shown by treatment of mouse tumours with a TGFBR inhibitor, which resulted in a reduction of neutrophils and reduced tumour size [125]. These neutrophils showed an upregulation of pro-inflammatory cytokines, chemokines, and iNOS and had a direct cytotoxic effect on tumour cells due to ROS secretion. Although TGF-β signaling can itself affect cancer cell survival, the reduction in tumour size was neutrophil dependent. Further studies have also implicated TGF-β as a regulator of G-MDSCs. These include a therapeutic effect of anti-TGFβ antibodies in a breast cancer model by depletion of MDSCs [209], and reduced tumour metastasis by myeloid-specific deletion of TGFBR2 in breast, lung and melanoma models [210]. More recently, the role of TGF-β in the recruitment of pro-tumour neutrophils has been described in mouse models of hepatocellular carcinoma through Cxcl5, the expression of which corresponds with disease severity in human patients [211]. Whilst these studies do not represent tumour initiation, they do indicate that TGF-B has a pro-tumour effect in mammalian cancer, including liver cancer, via recruitment and modulation of neutrophils.

6.6 Extracellular ATP attracts pro-tumour microglia/macrophages

Chia et al. (2019) showed that the trophic effect of microglia during glioblastoma tumour initiation was dependent upon Ca²⁺-mediated ATP release from PNCs via signaling through the P2y12 receptor [123]. This represents a repurposing of an endogenous mechanism found in both
zebrafish and mice, which governs microglia recruitment to areas of high calcium, such as injury and seizures [129–132]. Similarly, in a mouse model of glioma, ATP signaling through the purinergic receptor, P2x7R, promotes the recruitment of macrophages and microglia [212]. Although microglia are quite divergent in comparison to other macrophage types [213], ATP signaling though purinergic receptors also modulates the function of macrophages in inflammatory responses outside of the brain and promotes M2 polarisation in TAMs [214–216]. Therefore, this represents a mechanism for further study with regards to tumour initiation in other tissue types.

7. Future Perspectives

Zebrafish cancer models have shown that PNC-induced inflammation is an important player for tumour initiation. Hitherto, the role of inflammatory leukocytes at the pre-neoplastic stage was largely unknown. Imaging of translucent zebrafish larvae demonstrates that both neutrophils and macrophages are recruited in response to tumour initiation and have a trophic effect on PNCs. The ever-expanding collection of transgenic reporters and the efficient methods for genetic manipulation in the zebrafish provide a toolbox for the future analysis of cellular and signaling responses within the developing PNC niche. As such, the zebrafish model will provide much needed insight to support the development of novel strategies for cancer prevention.

Thus far, zebrafish studies have identified some of the chemoattractants, inflammatory mediators and trophic factors that contribute to PNC-induced inflammation. Whilst these signaling molecules correspond with pro-tumor responses in mouse and man, further research is required to confirm their mechanisms of action at the pre-neoplastic stage. There also remain additional signals that have yet to be discovered, for example, it is apparent that PGEs is not the sole leukocyte-derived factor influencing PNC proliferation at this stage [7]. Furthermore, the mechanisms that govern the pro-tumour phenotype of macrophages and neutrophils remain unclear. It would be worthwhile testing if other factors involved in polarising TAMs and TANs in the tumour microenvironment also play a role at the PNC niche. Inhibitors for blocking TAM recruitment and M2 polarisation are currently in clinical trials for cancer treatment and may also be promising for cancer prevention [217]. Considering the role of neutrophils in zebrafish studies of tumour initiation, targeting neutrophils in this way may also be an effective approach. Moreover, a more potent effect could be achieved by developing strategies to reprogram macrophages and neutrophils to an “M1” or “N1” state, wherein they may partake in anti-tumour responses. Some promise has been shown in this area, regarding the reprogramming of TAMs in mouse models [158,203,217,218], but this has yet to be explored in zebrafish. Traditional methods for studying leukocyte polarisation in mammalian immunology involve the analysis of multiple cell surface markers by flow cytometry, a method which is not compatible with zebrafish. However, the recent development of single-cell RNA-sequencing technologies will facilitate this research. This approach will provide insight into macrophage and neutrophil heterogeneity within the PNC microenvironment and identify marker genes that can be used for the development of novel transgenic reporters. It will also drive the discovery of novel factors that mediate trophic interactions between leukocytes and PNCs.

In addition to promoting PNC proliferation, zebrafish cancer models have also provided evidence that genes involved in angiogenesis and invasion are expressed at the pre-neoplastic stage by both PNCs and inflammatory cells [54,56,62,219]. This is of interest since these processes are traditionally associated with later stages of cancer but are likewise difficult to capture at early stages in mammalian models [2]. This presents angiogenesis and invasion, and their relationship with inflammation, as subjects for further study in zebrafish tumour initiation models. Dissecting the complex multicellular mechanisms at play in the PNC microenvironment will be facilitated by the ease of genetic manipulation in the zebrafish. For example, a system for cell-type specific CRISPR-mediated gene depletion has recently been developed [220,221]. This will help to pick apart the functions of specific cell types and the roles of pleiotropic genes.

Other likely components of the PNC microenvironment include extracellular vesicles (EVs) and stromal cells. EVs are known to transmit signals that modulate the behavior of recipient cells. Cancer-derived EVs have been shown to promote the M2 polarisation of TAMs in some cases, and
the expression of pro-inflammatory cytokines in others [222–224]. With the use of recently developed fluorescent labels for EVs in zebrafish it is possible to track their transit throughout zebrafish larvae [225,226]. In combination with a TNFα reporter, it was shown that EVs from tumour cells activated macrophages, which in turn enhanced metastasis of tumour cells in zebrafish. These reporters will be invaluable in addressing the question of whether PNC-derived EVs modulate host inflammatory cell function. Stromal cells within the PNC microenvironment are also of interest. “Cancer Associated Fibroblasts” have been identified as cancer-promoting agents in mammalian tumours [227], but their role at the pre-neoplastic stage remains largely unexplored. One study has recently showed that leukocytes recruited to hepatocyte PNCs produce serotonin, which activates mesenchymal stromal cells in the liver and encourages them to secrete TGF-β, amplifying pro-tumour inflammation [228]. This demonstrates a tumour promoting role for mesenchymal stromal cells during tumour liver tumour initiation and suggest a direction for future study in other tissues.

As well as detailed mechanistic studies, the zebrafish model is also amenable to high-throughput screening. The small size of zebrafish embryos allows for imaging of the whole animal and several individuals can be screened simultaneously. Precazzini et al. (2019) developed an automated, imaging-based screen with 384-well plates for modifiers of melanocyte hyper-proliferation in a melanoma model [229]. Taking advantage of existing fluorescently-tagged cancer models, it is possible to perform in vivo imaging based phenotypic drug screens for cancer preventative chemicals. The development of highly efficient methods for CRISPR-mediated gene deletion in first generation larvae, known as “crispants”, also provides the means to carry out high-throughput CRISPR screening for the discovery of novel targets [221]. Thus, the zebrafish is a powerful model with the potential to reveal mechanisms governing pre-neoplastic lesion development, and to test strategies for its prevention.

Author Contributions: A.E., H.M. Y.F. wrote the manuscript; A.E., Y.F. edited the manuscript.

Funding: Y.F. was funded by a Wellcome Trust Sir henry Dale Fellowship 100104/Z/12/Z; Y.F. received funding from Cancer Research UK 25107; Cancer Research UK 26931; H.M. was funded by a Sigrid Jusélius Fellowship; A. E. was funded by a MRC precision medicine DTP studentship.

Acknowledgments: We thank Dr Shereen Kadir for her help with the schematic in figure 1.

Conflicts of Interest: There are no conflicts of interest to declare from authors. The funders have no role in influencing views that expressed in this review article.

References
1. Flier, J.S.; Underhill, L.H.; Dvorak, H.F. Tumors: Wounds That Do Not Heal. N. Engl. J. Med. 1986, 315, 1650–1659.
2. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674.
3. Ruffell, B.; Coussens, L.M. Macrophages and Therapeutic Resistance in Cancer. Cancer Cell 2015, 27, 462–472.
4. Wu, L.; Saxena, S.; Awaji, M.; Singh, R.K. Tumor-associated neutrophils in cancer: Going pro. Cancers (Basel). 2019, 11.
5. Allavena, P.; Garlanda, C.; Borrello, M.G.; Sica, A.; Mantovani, A. Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 2008, 18, 3–10.
6. Feng, Y.; Santoriello, C.; Mione, M.; Hurlstone, A.; Martin, P. Live Imaging of Innate Immune Cell Sensing of Transformed Cells in Zebrafish Larvae: Parallels between Tumor Initiation and Wound Inflammation. PLoS Biol. 2010, 8, e1000562.
7. Feng, Y.; Renshaw, S.; Martin, P. Live Imaging of Tumor Initiation in Zebrafish Larvae Reveals a Trophic Role for Leukocyte-Derived PGE2. Curr. Biol. 2012, 22, 1253–1259.
8. Patton, E.E.; Zon, L.I. The art and design of genetic screens: Zebrafish. Nat. Rev. Genet. 2001, 2, 956–966.
9. Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.; McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human genome. *Nature* 2013, 496, 498–503.

10. Spitsbergen, J.M.; Buhler, D.R.; Peterson, T.S. Neoplasia and neoplasm-associated lesions in laboratory colonies of zebrafish emphasizing key influences of diet and aquaculture system design. *ILAR J.* 2012, 53, 114–125.

11. Storer, N.Y.; Zon, L.I. Zebrafish models of p53 functions. *Cold Spring Harb. Perspect. Biol.* 2010, 2.

12. Krens, S.F.G.; He, S.; Spantig, H.P.; Snaar-Jagalska, B.E. Characterization and expression patterns of the MAPK family in zebrafish. *Gene Expr. Patterns* 2006, 6, 1019–1026.

13. White, R.M.; Sessa, A.; Burke, C.; Bowman, T.; LeBlanc, J.; Geurts, A.; Hackett, P.B.; Largaespada, D.A.; McIvor, R.S.; et al. Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis. *Cell Stem Cell* 2008, 2, 183–189.

14. Langenau, D.M.; Traver, D.; Ferrando, A.A.; Kutok, J.L.; Aster, J.C.; Kanki, J.P.; Lin, S.; Prochownik, E.; Trede, N.S.; Zon, L.I.; et al. Myc-induced T cell leukemia in transgenic zebrafish. *Science (80-. ).* 2003, 299, 887–890.

15. Langenau, D.M.; Feng, H.; Berghmans, S.; Kanki, J.P.; Kutok, J.L.; Look, A.T. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. *Proc. Natl. Acad. Sci. U. S. A.* 2005, 102, 6068–6073.

16. Kawakami, K.; Shima, A.; Kawakami, N. Identification of a functional transposase of the Tol2 element, an Ac-like element from the Japanese medaka fish, and its transposition in the zebrafish germ lineage. *Proc. Natl. Acad. Sci. U. S. A.* 2000, 97, 11403–11408.

17. Barciunas, D.; Wangensteen, K.J.; Wilber, A.; Bell, J.; Geurts, A.; Sivasubbu, S.; Wang, X.; Hackett, P.B.; Largaespada, D.A.; McIvor, R.S.; et al. Harnessing a High Cargo-Capacity Transposon for Genetic Applications in Vertebrates. *PLoS Genet.* 2006, 2, e169.

18. Patton, E.E.; Widlund, H.R.; Kutok, J.L.; Kopani, K.R.; Amatruda, J.F.; Murphey, R.D.; Berghmans, S.; Mayhall, E.A.; Traver, D.; Fletcher, C.D.M.; et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. *Curr. Biol.* 2005, 15, 249–254.

19. Dovey, M.; White, R.M.; Zon, L.I. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. *Zebrafish* 2009, 6, 397–404.

20. Michailidou, C.; Jones, M.; Walker, P.; Kamarashev, J.; Kelly, A.; Hurlstone, A.F.L. Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model. *DMM Dis. Model. Mech.* 2009, 2, 399–411.

21. Santoriello, C.; Gennaro, E.; Anelli, V.; Distel, M.; Kelly, A.; Köster, R.W.; Hurlstone, A.; Mione, M. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish. *PLoS One* 2010, 5, 1–11.

22. Park, S.W.; Davison, J.M.; Rhee, J.; Hruban, R.H.; Maitra, A.; Leach, S.D. Oncogenic KRAS Induces Progenitor Cell Expansion and Malignant Transformation in Zebrafish Exocrine Pancreas. *Gastroenterology* 2008, 134, 2080–2090.

23. Zheng, W.; Li, Z.; Nguyen, A.T.; Li, C.; Emelyanov, A.; Gong, Z. Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. *PLoS One* 2014, 9, e91179.

24. Phelps, R.A.; Chidester, S.; Dehghanizadeh, S.; Phelps, J.; Sandoval, I.T.; Rai, K.; Broadbent, T.; Sarkar, S.; Burt, R.W.; Jones, D.A. A Two-Step Model for Colon Adenoma Initiation and Progression Caused by
APC Loss. *Cell* 2009, 137, 623–634.

25. Ju, B.; Chen, W.; Orr, B.A.; Spitsbergen, J.M.; Jia, S.; Eden, C.J.; Henson, H.E.; Taylor, M.R. Oncogenic KRAS promotes malignant brain tumors in zebrafish. *Mol. Cancer* 2015, 14, 18.

26. Osmani, N.; Goetz, J.G. Multiscale Imaging of Metastasis in Zebrafish. *Trends in Cancer* 2019, 5, 766–778.

27. Schiavone, M.; Rampazzo, E.; Casari, A.; Battilana, G.; Persano, L.; Moro, E.; Liu, S.; Leach, S.D.; Tiso, N.; Argenton, F. Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer. *Dis. Model. Mech.* 2014, 7, 883–894.

28. Zhu, S.; Lee, J.S.; Guo, F.; Shin, J.; Perez-Atayde, A.R.; Kutok, J.L.; Rodig, S.J.; Neuberg, D.S.; Helman, D.; Feng, H.; et al. Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. *Cancer Cell* 2012, 21, 362–373.

29. Kaufman, C.K.; Mosimann, C.; Fan, Z.P.; Yang, S.; Thomas, A.J.; Ablain, J.; Tan, J.L.; Fogley, R.D.; Van Rooijen, E.; Hagedorn, E.J.; et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. *Science (80-. ).* 2016, 351.

30. Tanimura, N.; Fujita, Y. Epithelial defense against cancer (EDAC). *Semin. Cancer Biol.* 2019.

31. Anton, K.A.; Kajita, M.; Narumi, R.; Fujita, Y.; Tada, M. Src-transformed cells hijack mitosis to extrude from the epithelium. *Nat. Commun.* 2018, 9, 4695.

32. Gu, Y.; Shea, J.; Slattum, G.; Firpo, M.A.; Alexander, M.; Golubovskaya, V.M.; Rosenblatt, J. Defective apical extrusion signaling contributes to aggressive tumor hallmarks. *Elife* 2015, e04069.

33. Knopf, F.; Schnabel, K.; Haase, C.; Pfeifer, K.; Anastassiadis, K.; Weidinger, G. Dually inducible TetON systems for tissue-specific conditional gene expression in zebrafish. *Proc. Natl. Acad. Sci. U. S. A.* 2010, 107, 19933–19938.

34. Emelyanov, A.; Parinov, S. Mifepristone-inducible LexPR system to drive and control gene expression in transgenic zebrafish. *Dev. Biol.* 2008, 320, 113–121.

35. Lepage, S.E.; Tada, M.; Bruce, A.E.E. Zebrafish Dynamin is required for maintenance of enveloping layer integrity and the progression of epiboly. *Dev. Biol.* 2014, 385, 52–66.

36. Hans, S.; Freudenreich, D.; Geffarth, M.; Kaslin, J.; Machate, A.; Brand, M. Generation of a non-leaky heat shock-inducible Cre line for conditional Cre/lox strategies in zebrafish. *Dev. Dyn.* 2011, 240, 108–115.

37. Laux, D.W.; Kelly, L.; Bravo, I.R.; Ramezani, T.; Feng, Y. Live imaging the earliest host innate immune response to preneoplastic cells using a zebrafish inducible KalTA4-ERT2/UAS system. *Methods Cell Biol.* 2017, 138, 137–150.

38. Ramezani, T.; Laux, D.W.; Bravo, I.R.; Tada, M.; Feng, Y. Live Imaging of Innate Immune and Preneoplastic Cell Interactions Using an Inducible Gal4/UAS Expression System in Larval Zebrafish Skin. *J. Vis. Exp.* 2015, e52107.

39. Park, J.T.; Leach, S.D. Zebrafish model of KRAS-initiated pancreatic cancer. *Animal Cells Syst. (Seoul).* 2018, 22, 353–359.

40. Yan, C.; Huo, X.; Wang, S.; Feng, Y.; Gong, Z. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. *J. Hepatol.* 2015, 63, 420–428.

41. Lu, J.W.; Raghuram, D.; Fong, P.S.A.; Gong, Z. Inducible Intestine-Specific Expression of kras V12 Triggers Intestinal Tumorigenesis In Transgenic Zebrafish. *Neoplasia (United States)* 2018, 20, 1187–1197.

42. Torraca, V.; Mostowy, S. Zebrafish Infection: From Pathogenesis to Cell Biology. *Trends Cell Biol.* 2018, 28, 143–156.

43. Martin, P.; Nunan, R. Cellular and molecular mechanisms of repair in acute and chronic wound healing.
44. Richardson, R.J. Parallels between vertebrate cardiac and cutaneous wound healing and regeneration. *npj Regen. Med.* 2018, 3, 1–9.

45. Ellett, F.; Pase, L.; Hayman, J.W.; Andrianopoulos, A.; Lieschke, G.J. mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish. *Blood* 2011, 117, e49–e56.

46. Walton, E.M.; Cronan, M.R.; Beerman, R.W.; Tobin, D.M. The Macrophage-Specific Promoter mfap4 Allows Live, Long-Term Analysis of Macrophage Behavior during Mycobacterial Infection in Zebrafish. *PLoS One* 2015, 10, e0138949.

47. Renshaw, S.A.; Loynes, C.A.; Trushell, D.M.I.; Elworthy, S.; Ingham, P.W.; Whyte, M.K.B. A transgenic zebrafish model of neutrophilic inflammation. *Blood* 2006, 108, 3976–3978.

48. Kitaguchi, T.; Kawakami, K.; Kawahara, A. Transcriptional regulation of a myeloid-lineage specific gene lysozyme C during zebrafish myelopoiesis. *Mech. Dev.* 2009, 126, 314–323.

49. Ju, B.; Chen, W.; Orr, B.A.; Spitsbergen, J.M.; Jia, S.; Eden, C.J.; Henson, H.E.; Taylor, M.R. Oncogenic KRAS promotes malignant brain tumors in zebrafish. *Mol. Cancer* 2015, 14, 18.

50. Powell, D.; Lou, M.; Barros Becker, F.; Huttenlocher, A. Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo. *Sci. Rep.* 2018, 8, 1–12.

51. Langenau, D.M.; Keefe, M.D.; Storer, N.Y.; Guyon, J.R.; Kutok, J.L.; Le, X.; Goessling, W.; Neuberg, D.S.; Kunkel, L.M.; Zon, L.I. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. *Genes Dev.* 2007, 21, 1382–1395.

52. Ignatius, M.S.; Chen, E.; Elpek, N.M.; Fuller, A.Z.; Tenente, I.M.; Clagg, R.; Liu, S.; Blackburn, J.S.; Linardic, C.M.; Rosenberg, A.E.; et al. In Vivo Imaging of Tumor-Propagating Cells, Regional Tumor Heterogeneity, and Dynamic Cell Movements in Embryonal Rhabdomyosarcoma. *Cancer Cell* 2012, 21, 680–693.
61. Mathias, J.R.; Perrin, B.J.; Liu, T.-X.; Kanki, J.; Look, A.T.; Huttenlocher, A. Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. *J. Leukoc. Biol.* 2006, 80, 1281–1288.

62. Freisinger, C.M.; Huttenlocher, A. Live Imaging and Gene Expression Analysis in Zebrafish Identifies a Link between Neutrophils and Epithelial to Mesenchymal Transition. *PLoS One* 2014, 9, e112183.

63. Antonio, N.; Bønnelykke-Behrndtz, M.L.; Ward, L.C.; Collin, J.; Christensen, I.J.; Steiniche, T.; Schmidt, H.; Feng, Y.; Martin, P. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. *EMBO J.* 2015, 34, 2219–2236.

64. Kelly, P.M.; Davison, R.S.; Bliss, E.; McGee, J.O. Macrophages in human breast disease: a quantitative immunohistochemical study. *Br. J. Cancer* 1988, 57, 174–7.

65. Van Overmeire, E.; Laoui, D.; Keirse, J.; Van Ginderachter, J.A.; Sarukhan, A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. *Front. Immunol.* 2014, 5, 127.

66. Noy, R.; Pollard, J.W. Tumor-Associated Macrophages: From Mechanisms to Therapy. *Immunity* 2014, 41, 49–61.

67. Ojalvo, L.S.; King, W.; Cox, D.; Pollard, J.W. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. *Am. J. Pathol.* 2009, 174, 1048–1064.

68. Gabriovich, D.I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated regulation of myeloid cells by tumours. *Nat. Rev. Immunol.* 2012, 12, 253–268.

69. Qian, B.Z.; Pollard, J.W. Macrophage Diversity Enhances Tumor Progression and Metastasis. *Cell* 2010, 141, 39–51.

70. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. *J. Clin. Invest.* 2012, 122, 787–795.

71. Yang, M.; McKay, D.; Pollard, J.W.; Lewis, C.E. Diverse functions of macrophages in different tumor microenvironments. *Cancer Res.*, 2018, 78, 5492–5503.

72. Noy, R.; Pollard, J.W. Tumor-associated macrophages: from mechanisms to therapy. 2014.

73. Coffelt, S.B.; Hughes, R.; Lewis, C.E. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. *Biochim. Biophys. Acta - Rev. Cancer* 2009, 1796, 11–18.

74. Lin, E.Y.; Pollard, J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. *Cancer Res.* 2007, 67, 5064–5066.

75. Kitamura, T.; Qian, B.Z.; Pollard, J.W. Immune cell promotion of metastasis. *Nat. Rev. Immunol.* 2015, 15, 73–86.

76. Britto, D.D.; Wyroba, B.; Chen, W.; Lockwood, R.A.; Tran, K.B.; Shepherd, P.R.; Hall, C.J.; Crosier, K.E.; Crosier, P.S.; Astin, J. Macrophages enhance Vegfa-driven angiogenesis in an embryonic zebrafish tumour xenograft model. *DMM Dis. Model. Mech.* 2018, 11.

77. Rob-Johnson, M.; Shah, A.N.; Stonick, J.A.; Poudel, K.R.; Kargl, J.; Yang, G.H.; di Martino, J.; Hernandez, R.E.; Gast, C.E.; Zarour, L.R.; et al. Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo. *Dev. Cell* 2017, 43, 549-562.e6.

78. Masucci, M.T.; Minopoli, M.; Carriero, M.V. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. *Front. Oncol.* 2019, 9, 1146.

79. Shen, M.; Hu, P.; Donskov, F.; Wang, G.; Liu, Q.; Du, J. Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis. *PLoS One* 2014, 9, e98259.

80. Gentles, A.J.; Newman, A.M.; Liu, C.L.; Bratman, S. V.; Feng, W.; Kim, D.; Nair, V.S.; Xu, Y.; Khuong, A.
Hoang, C.D.; et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 2015, 21, 938–945.

81. Galdiero, M.R.; Varricchi, G.; Loffredo, S.; Mantovani, A.; Marone, G. Roles of neutrophils in cancer growth and progression. J. Leukoc. Biol. 2018, 103, 457–464.

82. Gonzalez, H.; Hagerling, C.; Werb, Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018, 32, 1267–1284.

83. Finisguerra, V.; Di Conza, G.; Di Matteo, M.; Serneels, J.; Costa, S.; Thompson, A.A.R.; Wauters, E.; Walmsley, S.; Prener, H.; Granot, Z.; et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015, 522, 349–353.

84. Weinberg, F.; Ramnath, N.; Nagrath, D. Reactive oxygen species in the tumor microenvironment: An overview. Cancers (Basel). 2019, 11.

85. Koga, Y.; Matsuzaki, A.; Suminoe, A.; Hatta, T. Neutrophil-Derived TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Mechanism of Antitumor Effect by Neutrophils. Cancer Res. 2004, 64, 1037–1043.

86. Governa, V.; Trella, E.; Mele, V.; Tornillo, L.; Amicarella, F.; Cremonesi, E.; Muraro, M.G.; Xu, H.; Droeser, R.; Däster, S.R.; et al. The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer. Clin. Cancer Res. 2017, 23, 3847–3858.

87. He, S.; Lamers, G.E.M.; Beenakker, J.W.M.; Cui, C.; Ghotra, V.P.S.; Danen, E.H.J.; Meijer, A.H.; Spaïnk, H.P.; Snaar-Jagalska, B.E. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J. Pathol. 2012, 227, 431–445.

88. Tulotta, C.; Snaar-Jagalska, B.E. CXCR4 signalling, metastasis and immunotherapy: zebrafish xenograft model as translational tool for anti-cancer discovery. J. Cancer Metastasis Treat. 2019, 2019.

89. Huo, X.; Li, H.; Li, Z.; Yan, C.; Agrawal, I.; Mathavan, S.; Liu, J.; Gong, Z. Transcriptomic profiles of tumor-associated neutrophils reveal prominent roles in enhancing angiogenesis in liver tumorigenesis in zebrafish. Sci. Rep. 2019, 9.

90. Peñaloza, H.F.; Alvarez, D.; Muñoz-Durango, N.; Schultz, B.M.; González, P.A.; Kalergis, A.M.; Bueno, S.M. The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study. J. Leukoc. Biol. 2019, 105, 857–872.

91. Kumar, V.; Patel, S.; Tcyganov, E.; Gabrilovich, D.I. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016, 37, 208–220.

92. Giese, M.A.; Hind, L.E.; Hutterlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 2019, 133, 2159–2167.

93. Cassetta, L.; Fragkogianni, S.; Sims, A.H.; Coussens, L.M.; Smith, H.O.; Pollard Correspondence, J.W. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. 2019.

94. Brandau, S.; Moses, K.; Lang, S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins? Semin. Cancer Biol. 2013, 23, 171–182.

95. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159–170.

96. Solomon, E.; Voss, R.; Hall, V.; Bodmer, W.F.; Jass, J.R.; Jeffreys, A.J.; Lucibello, F.C.; Patel, I.; Rider, S.H. Chromosome 5 allele loss in human colorectal carcinomas. Nature 1988, 328, 616–619.

97. Bodmer, W.F.; Bailey, C.J.; Bodmer, J.; Bussey, H.J.R.; Ellis, A.; Gorman, P.; Lucibello, F.C.; Murday, V.A.; Rider, S.H.; Scambler, P.; et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1988, 328, 614–616.
98. Moser, A.R.; Pitot, H.C.; Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* (80-. ). 1990, 247, 322–324.

99. Rowan, A.J.; Lamlim, H.; Ilyas, M.; Wheeler, J.; Straub, J.; Papadopoulou, A.; Hicknell, D.; Bodmer, W.F.; Tomlinson, I.P.M. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits.” *Proc. Natl. Acad. Sci. U. S. A.* 2000, 97, 3352–3357.

100. Takahashi, M.; Mutoh, M.; Kawamori, T.; Sugimura, T.; Wakabayashi, K. Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. *Carcinogenesis* 2000, 21, 1319–1327.

101. Pugh, S.; Thomas, G.A.O. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. *Gut* 1994, 35, 675–678.

102. Rao, C. V.; Indranie, C.; Simi, B.; Reddy, B.S.; Manning, P.T.; Connor, J.R. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. *Cancer Res.* 2002, 62, 165–170.

103. Mutoh, M.; Watanabe, K.; Kitamura, T.; Shoji, Y.; Takahashi, M.; Kawamori, T.; Sugimura, T.; Wakabayashi, K.; Tani, K.; Kobayashi, M.; et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. *Cancer Res.* 2002, 62, 28–32.

104. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 1996, 87, 803–9.

105. Sonoshita, M.; Takaku, K.; Sasaki, N.; Sugimoto, Y.; Ushikubi, F.; Narumiya, S.; Oshima, M.; Taketo, M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. *Nat. Med.* 2001, 7, 1048–1051.

106. Chulada, P.C.; Thompson, M.B.; Mahler, J.F.; Doyle, C.M.; Gaul, B.W.; Lee, C.; Tiano, H.F.; Morham, S.G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs1, as well as Ptgs2, reduces intestinal tumorigenesis in Min mice. *Cancer Res.* 2000, 60, 4705–8.

107. Steinbach, G.; Lynch, P.M.; Phillips, R.K.S.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N. Engl. J. Med.* 2000, 342, 1946–1952.

108. Meyskens, F.L.; McLaren, C.E.; Pelot, D.; Fujikawa-Brooks, S.; Carpenter, P.M.; Hawk, E.; Kelloff, G.; Lawson, M.J.; Kidao, J.; McCracken, J.; et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. *Cancer Prev. Res.* 2008, 1, 32–38.

109. Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Breazna, A.; Kim, K.M.; Tang, J.; Rosenstein, R.B.; Umar, A.; Bagheri, D.; et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. *Cancer Prev. Res.* 2009, 2, 310–321.

110. Gala, M.K.; Chan, A.T. Molecular Pathways Molecular Pathways: Aspirin and Wnt Signaling—A Molecularly Targeted Approach to Cancer Prevention and Treatment. *Clin Cancer Res* 2015, 21.

111. Senior, K. COX-2 inhibitors: Cancer prevention or cardiovascular risk? *Lancet Oncol.* 2005, 6, 68.

112. Stasinopoulos, I.; Shah, T.; Penet, M.-F.; Krishnamachary, B.; Bhujwalla, Z.M. COX-2 in cancer: Gordian knot or Achilles heel? *Front. Pharmacol.* 2013, 4, 34.

113. Martín-Sanz, P.; Casado, M.; Boscá, L. Cyclooxygenase-2 in liver dysfunction and carcinogenesis: Facts and perspectives. *World J. Gastroenterol.* 2017, 23, 3572–3580.

114. Krysan, K.; Reckamp, K.; Sharma, S.; Dubinett, S. The Potential and Rationale for COX-2 Inhibitors in
Lung Cancer. *Anticancer. Agents Med. Chem.* **2008**, *6*, 209–220.

115. Jiang, J.; Qiu, J.; Li, Q.; Shi, Z. Prostaglandin E2 Signaling: Alternative Target for Glioblastoma? *Trends in Cancer* **2017**, *3*, 75–78.

116. Omura, N.; Griffith, M.; Vincent, A.; Li, A.; Hong, S.M.; Walter, K.; Borges, M.; Goggin, M. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. *Mol. Cancer Res.* **2010**, *8*, 821–832.

117. Hill, R.; Li, Y.; Tran, L.M.; Dry, S.; Calvopina, J.H.; Garcia, A.; Kim, C.; Wang, Y.; Donahue, T.R.; Herschman, H.R.; et al. Cell intrinsic role of COX-2 in pancreatic cancer development. *Mol. Cancer Ther.* **2012**, *11*, 2127–2137.

118. McClellan, J.L.; Mark Davis, J.; Stein, J.; Enos, R.T.; Jung, S.H.; Carson, J.A.; Pena, M.M.; Carnevale, K.A.; Berger, F.G.; Murphy, A. E. Inking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: Role of MCP-1. *Am. J. Physiol. - Gastrointest. Liver Physiol.* **2012**, *303*, G1087.

119. Jamieson, T.; Clarke, M.; Steele, C.W.; Samuel, M.S.; Neumann, J.; Jung, A.; Huels, D.; Olson, M.F.; Das, S.; Nibbs, R.J.B.; et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. *J. Clin. Invest.* **2012**, *122*, 3127–3144.

120. Jayakumar, A.; Bothwell, A.L.M. Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response. *Neoplasia (United States)* **2012**, *19*, 595–606.

121. Katoh, H.; Wang, D.; Daikoku, T.; Sun, H.; Dey, S.K.; DuBois, R.N. CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis. *Cancer Cell* **2013**, *24*, 631–644.

122. Chia, K.; Mazzolini, J.; Mione, M.; Sieger, D. Tumor initiating cells induce ccr4- mediated infiltration of pro-tumoral macrophages into the brain. *Elife* **2018**, *7*. 

123. Li, Y.; Du, X.F.; Liu, C.S.; Wen, Z.L.; Du, J.L. Reciprocal Regulation between Resting Microglial Dynamics and Neuronal Activity In Vivo. *Dev. Cell* **2012**, *23*, 1189–1202.

124. Eyo, U.B.; Swiatkowski, P.; Mukherjee, A.; Bispo, A.; Wu, L.J. Neuronal hyperactivity recruits
microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J. Neurosci. 2014, 34, 10528–10540.

132. Eyo, U.B.; Gu, N.; De, S.; Dong, H.; Richardson, J.R.; Wu, L.J. Modulation of microglial process convergence toward neuronal dendrites by extracellular calcium. J. Neurosci. 2015, 35, 2417–2422.

133. Massara, M.; Persico, P.; Bonavita, O.; Poeta, V.M.; Locati, M.; Simonelli, M.; Bonecchi, R. Neutrophils in gliomas. Front. Immunol. 2017, 8.

134. Feng, Y.; Renshaw, S.; Martin, P. Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE2. Curr. Biol. 2012, 22, 1253–1259.

135. Krelin, Y.; Voronov, E.; Dotan, S.; Elkabets, M.; Reich, E.; Fogel, M.; Huszar, M.; Iwakura, Y.; Segal, S.; Dinarello, C.A.; et al. Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007, 67, 1062–1071.

136. Rakoff-Nahoum, S.; Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (80-. ). 2007, 317, 124–127.

137. Cataisson, C.; Salcedo, R.; Hakim, S.; Moffitt, B. Andrea, A.; Wright, L.; Yi, M.; Stephens, R.; Dai, R.M.; Lyakh, L.; Schenten, D.; et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J. Exp. Med. 2012, 209, 1689–1702.

138. Weber, A.; Wasiliew, P.; Kracht, M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010, 3, cm1–cm1.

139. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1.

140. Demetri, G.D.; Ernst, T.J.; Pratt, E.S.; Zentz, B.W.; Rheinwald, J.G.; Griffin, J.D. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J. Clin. Invest. 1990, 86, 1261–1269.

141. Castelli, C.; Sensi, M.; Lupetti, R.; Mortarini, R.; Panceri, P.; Anichini, A.; Parmiani, G. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res. 1994, 54, 4785–90.

142. Liu, J.; Yang, G.; Thompson-Lanza, J.A.; Glassman, A.; Hayes, K.; Patterson, A.; Marquez, R.T.; Auersperg, N.; Yu, Y.; Hahn, W.C.; et al. A genetically defined model for human ovarian cancer. Cancer Res. 2004, 64, 1655–63.

143. Ancrile, B.B.; O’Hayer, K.M.; Counter, C.M. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol. Interv. 2008, 8, 22–7.

144. Ancrile, B.; Lim, K.H.; Counter, C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21, 1714–1719.

145. Moore, R.J.; Owens, D.M.; Stamp, G.; Arnott, C.; Burke, F.; East, N.; Holdsworth, H.; Turner, L.; Rollins, B.; Pasparakis, M.; et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat. Med. 1999, 5, 828–831.

146. Arnott, C.H.; Scott, K.A.; Moore, R.J.; Robinson, S.C.; Thompson, R.G.; Balkwill, F.R. Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene 2004, 23, 1902–1910.

147. Knight, B.; Yeoh, G.C.T.; Husk, K.L.; Ly, T.; Abraham, L.J.; Yu, C.; Rhim, J.A.; Fausto, N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 2000, 192, 1809–1818.

148. Sedger, L.M.; McDermott, M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014, 25,
149. Manthey, C.L.; Johnson, D.L.; Illig, C.R.; Tuman, R.W.; Zhou, Z.; Baker, J.F.; Chaikin, M.A.; Donatelli, R.R.; Franks, C.F.; Zeng, L.; et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. *Mol. Cancer Ther.* 2009, 8, 3151–3161.

150. Nowicki, A.; Szenajch, J.; Ostrowska, G.; Wojtowicz, A.; Wojtowicz, K.; Kruzewski, A.A.; Maruszynski, M.; Aukerman, S.L.; Witkow-Jedrzejczak, W. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: Evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. *Int. J. Cancer* 1996, 65, 112–119.

151. Aharinejad, S.; Paulus, P.; Sioud, M.; Hofmann, M.; Zins, K.; Schäfer, R.; Stanley, E.R.; Abraham, D. Colony-stimulating factor 1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. *Cancer Res.* 2004, 64, 5378–5384.

152. Aharinejad, S.; Abraham, D.; Paulus, P.; Abri, H.; Hofmann, M.; Grossschmidt, K.; Schäfer, R.; Stanley, E.R.; Hofbauer, R. Colony-stimulating Factor 1 Antisense Treatment Suppresses Growth of Human Tumor Xenografts in Mice 2002; Vol. 62;.

153. Cannarile, M.A.; Weisser, M.; Jacob, W.; Jegg, A.M.; Ries, C.H.; Rüttinger, D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. *J. Immunother. Cancer* 2017, 5, 53.

154. Pyonteck, S.M.; Gadea, B.B.; Wang, H.W.; Gocheva, V.; Hunter, K.E.; Tang, L.H.; Joyce, J.A. Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. *Oncogene* 2012, 31, 1459–1467.

155. Ryder, M.; Gild, M.; Hohl, T.M.; Pamer, E.; Knauf, J.; Ghossein, R.; Joyce, J.A.; Fagin, J.A. Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression. *PLoS One* 2013, 8, e54302.

156. Lin, E.Y.; Nguyen, A. V.; Russell, R.G.; Pollard, J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. *J. Exp. Med.* 2001, 193, 727–739.

157. Oguma, K.; Oshima, H.; Aoki, M.; Uchio, R.; Naka, K.; Nakamura, S.; Hirao, A.; Saya, H.; Takeo, M.M.; Oshima, M. Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells. *EMBO J.* 2008, 27, 1671–1681.

158. Quail, D.F.; Bowman, R.L.; Akkari, L.; Quick, M.L.; Schuhmacher, A.J.; Huse, J.T.; Holland, E.C.; Sutton, J.C.; Joyce, J.A. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. *Science* (80-. ). 2016, 352, aad3018–aad3018.

159. Boimel, P.J.; Smirnova, T.; Zhou, Z.N.; Wyckoff, J.; Park, H.; Coniglio, S.J.; Qian, B.-Z.; Stanley, E.R.; Cox, D.; Pollard, J.W.; et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. *Breast Cancer Res.* 2012, 14, R23.

160. Arwert, E.N.; Harney, A.S.; Entenberg, D.; Wang, Y.; Sahai, E.; Pollard, J.W.; Condeelis, J.S. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation. *Cell Rep.* 2018, 23, 1239–1248.

161. Ping, Y.F.; Yao, X.H.; Jiang, J.Y.; Zhao, L.T.; Yu, S.C.; Jiang, T.; Lin, M.C.M.; Chen, J.H.; Wang, B.; Zhang, R.; et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. *J. Pathol.* 2011, 224, 344–354.

162. Gravina, G.L.; Mancini, A.; Colapietro, A.; Vitale, F.; Vetuschi, A.; Pompili, S.; Rossi, G.; Marampon, F.; Richardson, P.J.; Patient, L.; et al. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. *Tumor
163. Balkwill, F. The significance of cancer cell expression of the chemokine receptor CXCR4. *Semin. Cancer Biol.* 2004, 14, 171–179.

164. Walenkamp, A.M.E.; Lapa, C.; Herrmann, K.; Wester, H.J. CXCR4 ligands: The next big hit? *J. Nucl. Med.* 2017, 58, 775-82S.

165. Yu, X.; Wang, D.; Wang, X.; Sun, S.; Zhang, Y.; Wang, S.; Miao, R.; Xu, X.; Qu, X. CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. *J. Exp. Clin. Cancer Res.* 2019, 38, 32.

166. Schmid, M.C.; Avraamides, C.J.; Foubert, P.; Shaked, Y.; Kang, S.W.; Kerbel, R.S.; Varner, J.A. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. *Cancer Res.* 2011, 71, 6965–6975.

167. Tulotta, C.; Stefanescu, C.; Chen, Q.; Torraca, V.; Meijer, A.H.; Snaar-Jagalska, B.E. CXCR4 signaling regulates metastatic onset by controlling neutrophil motility and response to malignant cells. *Sci. Rep.* 2019, 9, 1–16.

168. Jablonska, J.; Leschner, S.; Westphal, K.; Lienenklaus, S.; Weiss, S. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. *J. Clin. Invest.* 2010, 120, 1151–1164.

169. Benedicto, A.; Romayor, I.; Arteta, B. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver. *Oncol. Rep.* 2018, 39, 2022–2030.

170. Shive, H.R.; West, R.R.; Embree, L.J.; Sexton, J.M.; Hickstein, D.D. Expression of KRASG12V in zebrafish gills induces hyperplasia and CXCL8-associated inflammation. *Zebrafish* 2015, 12, 221–229.

171. Gong, L.; Cumpian, A.M.; Caetano, M.S.; Ochoa, C.E.; De la Garza, M.M.; Lapid, D.J.; Mirabalfontainjad, S.G.; Dickey, B.F.; Zhou, Q.; Moghaddam, S.J. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. *Mol. Cancer* 2013, 12, 154.

172. Ichikawa, M.; Williams, R.; Wang, L.; Vogl, T.; Srikrishna, G. S100A8/A9 activate key genes and pathways in colon tumor progression. *Mol. Cancer Res.* 2011, 9, 133–148.

173. Dominguez, C.; McCampbell, K.K.; David, J.M.; Palena, C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. *JCI Insight* 2017, 2.

174. Tazzyman, S.; Barry, S.T.; Ashton, S.; Wood, P.; Blakey, D.; Lewis, C.E.; Murdoch, C.; Chi, Y-Y.; Shang, K.; Bai, Y-P.; Wang, C.; Wang, Z.; Gu, H-Y.; Du, X.; Zhou, X-Y.; Zheng, C-L.; Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 March 2020 DOI: 10.20944/preprints202003.0254.v1
Mukaida, N.; et al. Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice. *PLoS One* **2012**, *7*, e51848.

180. Asfaha, S.; Dubeykovskiy, A.N.; Tomita, H.; Yang, X.; Stokes, S.; Shibata, W.; Friedman, R.A.; Ariyama, H.; Dubeykovskaya, Z.A.; Muthupalani, S.; et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. *Gastroenterology* **2013**, *144*, 155–166.

181. Mariani, F.; Sena, P.; Roncucci, L. Inflammatory pathways in the early steps of colorectal cancer development. *World J. Gastroenterol.* **2014**, *20*, 9716–9731.

182. Cheng, H.; Wang, Z.; Fu, L.; Xu, T. Macrophage polarization in the development and progression of ovarian cancers: An overview. *Front. Oncol.* **2019**, *9*.

183. Mishalian, I.; Bayuh, R.; Levy, L.; Zolotarov, L.; Michaeli, J.; Fridlender, Z.G. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. *Cancer Immunol. Immunother.* **2013**, *62*, 1745–1756.

184. Hagemann, T.; Wilson, J.; Burke, F.; Kulbe, H.; Li, N.F.; Plüddemann, A.; Charles, K.; Gordon, S.; Balkwill, F.R. Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. *J. Immunol.* **2006**, *176*, 5023–5032.

185. Nguyen-Chi, M.; Laplace-Builhe, B.; Travnickova, J.; Luz-Crawford, P.; Tejedor, G.; Phan, Q.T.; Duroux-Richard, I.; Levraud, J.P.; Kissa, K.; Lutfalla, G.; et al. Identification of polarized macrophage subsets in zebrafish. *Elife* **2015**, *4*.

186. Krzyszczak, P.; Schloss, R.; Palmer, A.; Berthaume, F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. *Front. Physiol.* **2018**, *9*.

187. Wilgus, T.A.; Roy, S.; McDaniel, J.C. Neutrophils and Wound Repair: Positive Actions and Negative Reactions. *Adv. Wound Care* **2013**, *2*, 379–388.

188. Hull, M.A.; Booth, J.K.; Tisbury, A.; Scott, N.; Bonifer, C.; Markham, A.F.; Coletta, P.L. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. *Br. J. Cancer* **1999**, *79*, 1399–1405.

189. Bamba, H.; Ota, S.; Kato, A.; Adachi, A.; Itoyama, S.; Matsuzaki, F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. *Int. J. Cancer* **1999**, *83*, 470–475.

190. Tanaka, S.; Tatsuguchi, A.; Futagami, S.; Gudis, K.; Wada, K.; Seo, T.; Mitsui, K.; Yonezawa, M.; Nagata, K.; Fujimori, S.; et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. *Gut* **2006**, *55*, 54–61.

191. Smakman, N.; Kranenburg, O.; Vogten, J.M.; Bloemendaal, A. LA; van Diest, P.; Borel Rinkes, I.H. Cyclooxygenase-2 is a Target of KRAS D12, Which Facilitates the Outgrowth of Murine C26 Colorectal Liver Metastases; 2005;

192. Liu, W.; Reimnuth, N.; Stoeltzing, O.; Parikh, A.A.; Tellez, C.; Williams, S.; Jung, Y.D.; Fan, F.; Takeda, A.; Akagi, M.; et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. *Cancer Res.* **2003**, *63*, 3632–6.

193. Attiq, A.; Jalil, J.; Husain, K.; Ahmad, W. Raging the war against inflammation with natural products. *Front. Pharmacol.* **2018**, *9*, 976.

194. Lee, K.W.; Kim, M.S.; Kang, N.J.; Kim, D.H.; Surh, Y.J.; Lee, H.J.; Moon, A. H-Ras selectively
up-regulates MMP-9 and COX-2 through activation of EKK1/2 and NF-kB: An implication for invasive phenotype in rat liver epithelial cells. *Int. J. Cancer* 2006, 119, 1767–1775.

196. Medeiros, A.; Peres-Buzalaf, C.; Fortino Verdan, F.; Serezani, C.H. Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs. *Mediators Inflamm.* 2012, 2012, 327568.

197. Kalinski, P. Regulation of Immune Responses by Prostaglandin E2. *J. Immunol.* 2012, 188, 21–28.

198. MacKenzie, K.F.; Clark, K.; Naqvi, S.; McGuire, V.A.; Nöehren, G.; Kristariyanto, Y.; van den Bosch, M.; Mudaliar, M.; McCarthy, P.J.; et al. PGE2 Induces Macrophage IL-10 Production and a Regulatory-like Phenotype via a Protein Kinase A–SIK–CRTC3 Pathway. *J. Immunol.* 2013, 190, 565–577.

199. Luan, B.; Yoon, Y.S.; Lay, J. Le; Kaestner, K.H.; Hedrick, S.; Montminy, M. CREB pathway links PGE2 signaling with macrophage polarization. *Proc. Natl. Acad. Sci. U. S. A.* 2015, 112, 15642–15647.

200. Tang, T.; Scambler, T.E.; Smallie, T.; Cuniliffe, H.E.; Ross, E.A.; Rosner, D.R.; O’Neil, J.D.; Clark, A.R. Macrophage responses to lipopolysaccharide are modulated by a feedback loop involving prostaglandin E2, dual specificity phosphatase 1 and tristetraprolin. *Sci. Rep.* 2017, 7, 1–13.

201. Agard, M.; Asakrakah, S.; Morici, L.A. PGE2 suppression of innate immunity during mucosal bacterial infection. *Front. Cell. Infect. Microbiol.* 2013, 4, 45.

202. Loynes, C.A.; Lee, J.A.; Robertson, A.L.; Steel, M.J.G.; Ellett, F.; Feng, Y.; Levy, B.D.; Whyte, M.K.B.; Renshaw, S.A. PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. *Sci. Adv.* 2018, 4, eaar8320.

203. Van Dalen, F.J.; Van Stevendaal, M.H.M.E.; Fennemann, F.L.; Verdoes, M.; Ilina, O. Molecular repolarisation of tumour-associated macrophages. *Molecules* 2019, 24.

204. Nakanishi, Y.; Nakatsuji, M.; Seno, H.; Ishizu, S.; Akitake-Kawano, R.; Kanda, K.; Ueo, T.; Komukado, H.; Kawada, M.; Minami, M.; et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in Apc Min/1 mouse polyps. *Carcinogenesis* 2011, 32, 1333–1339.

205. Na, Y.R.; Yoon, Y.N.; Son, D.I.; Seok, S.H. Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer Model. *PLoS One* 2013, 8.

206. Sinha, P.; Clements, V.K.; Fulton, A.M.; Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. *Cancer Res.* 2007, 67, 4507–4513.

207. Rodríguez-Ubreva, J.; García-Gomez, A.; Ballestar, E. Epigenetic mechanisms of myeloid differentiation in the tumor microenvironment. *Curr. Opin. Pharmacol.* 2017, 35, 20–29.

208. Obermajer, N.; Muthuswamy, R.; Odunsi, K.; Edwards, R.P.; Kalinski, P. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. *Cancer Res.* 2011, 71, 7463–7470.

209. Li, Z.; Pang, Y.; Gara, S.K.; Achyut, B.R.; Heger, C.; Goldsmith, P.K.; Loning, S.; Yang, L. Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression. *Int. J. Cancer* 2012, 131, 2584–2595.

210. Pang, Y.; Gara, S.K.; Achyut, B.R.; Li, Z.; Yan, H.H.; Day, C.P.; Weiss, J.M.; Trinchieri, G.; Morris, J.C.; Yang, L. TGF-β Signaling in myeloid cells is required for tumor metastasis. *Cancer Discov.* 2013, 3, 936–951.

211. Haider, C.; Hnat, J.; Wagner, R.; Huber, H.; Timelthalger, G.; Grubinger, M.; Couluarn, C.; Schreiner, W.; Schlangen, K.; Sieghart, W.; et al. Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. *Hepatology* 2019, 69, 222–236.
212. Fang, K.M.; Wang, Y.L.; Huang, M.C.; Sun, S.H.; Cheng, H.; Tzeng, S.F. Expression of macrophage inflammatory protein-1α and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: Involvement of ATP and P2X7 receptor. *J. Neurosci. Res.* 2011, 89, 199–211.

213. Haage, V.; Semtner, M.; Vidal, R.O.; Hernandez, D.P.; Pong, W.W.; Chen, Z.; Hambardzumyan, D.; Magrini, V.; Ly, A.; Walker, J.; et al. Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. *Acta Neuropathol. Commun.* 2019, 7, 20.

214. Desai, B.N.; Leitinger, N. Purinergic and calcium signaling in macrophage function and plasticity. *Front. Immunol.* 2014, 5.

215. Di Virgilio, F.; Sarti, A.C.; Falzoni, S.; De Marchi, E.; Adinolfi, E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. *Nat. Rev. Cancer* 2018, 18, 601–618.

216. De Marchi, E.; Orioli, E.; Pegoraro, A.; Sangaletti, S.; Portararo, P.; Curti, A.; Colombo, M.P.; Di Virgilio, F.; Adinolfi, E. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. *Oncogene* 2019, 38, 3636–3650.

217. Cassetta, L.; Pollard, J.W. Targeting macrophages: therapeutic approaches in cancer. *Nat. Rev. Drug Discov.* 2018, 17, 887–904.

218. Kowal, J.; Kornete, M.; Joyce, J.A. Re-education of macrophages as a therapeutic strategy in cancer. *Immunotherapy* 2019, 11, 677–689.

219. van den Berg, M.; MacCarthy-Morrogh, L.; Carter, D.; Morris, J.; Bravo, I.R.; Feng, Y.; Martin, P. Active and opportunistic breaching of the basement membrane by immune cells during tumour initiation. *Developmental Cell.* Under Submiss. 2018.

220. Ablain, J.; Durand, E.M.; Yang, S.; Zhou, Y.; Zon, L.I. A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. *Dev. Cell* 2015, 32, 756–764.

221. Cornet, C.; Di Donato, V.; Terriente, J. Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. *Front. Pharmacol.* 2018, 9, 703.

222. Andrade, L.N. de S.; Otake, A.H.; Cardim, S.G.B.; da Silva, F.I.; Ikoma Sakamoto, M.M.; Furuya, T.K.; Uno, M.; Pasini, F.S.; Chammas, R. Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy. *Sci. Rep.* 2019, 9, 1–12.

223. Shinohara, H.; Kuranaga, Y.; Kumazaki, M.; Sugito, N.; Yoshikawa, Y.; Takai, T.; Taniguchi, K.; Ito, Y.; Akao, Y. Regulated Polarization of Tumor-Associated Macrophages by miR-145 via Colorectal Cancer-Derived Extracellular Vesicles. *J. Immunol.* 2017, 199, 1505–1515.

224. Han, L.; Lam, E.W.F.; Sun, Y. Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. *Mol. Cancer* 2019, 18, 1–14.

225. Hyenne, V.; Ghoroghi, S.; Collot, M.; Bons, J.; Follain, G.; Harlepp, S.; Mary, B.; Bauer, J.; Mercier, L.; Busnelli, I.; et al. Studying the Fate of Tumor Extracellular Vesicles at High Spatiotemporal Resolution Using the Zebrafish Embryo. *Dev. Cell* 2019, 48, 554-572.e7.

226. Collot, M.; Ashokkumar, P.; Anton, H.; Bountant, E.; Faklaris, O.; Galli, T.; Mély, Y.; Danglot, L.; Klymchenko, A.S. MemBright: A Family of Fluorescent Membrane Probes for Advanced Cellular Imaging and Neuroscience. *Cell Chem. Biol.* 2019, 26, 600-614.e7.

227. Sahai, E.; Astsaturov, I.; Cukierman, E.; DeNardo, D.G.; Egeblad, M.; Evans, R.M.; Fearon, D.; Greten, F.R.; Hingorani, S.R.; Hunter, T.; et al. A framework for advancing our understanding of cancer-associated fibroblasts. *Nat. Rev. Cancer* 2020, 20, 174–186.

228. Yang, Q.; Yan, C.; Gong, Z. Interaction of hepatic stellate cells with neutrophils and macrophages in the
liver following oncogenic kras activation in transgenic zebrafish. *Sci. Rep.* **2018**, *8*, 1–12.

229. Precazzini, F.; Pancher, M.; Gatto, P.; Tushe, A.; Adami, V.; Anelli, V.; Mione, M.C. Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model. *Dev. Biol.* **2020**, *457*, 215–225.